Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity.
It should be used with a weight loss plan and physical activity.
Blockbuster weight loss and diabetes drugs like Wegovy and Ozempic may be associated with an increased risk of three rare, but severe, stomach conditions in non-diabetic patients, according to a new epidemiological study released Thursday.
Their research is the first large, population-level study to examine the risk of serious stomach conditions in non-diabetic patients specifically using GLP-1s for weight loss.
People with diabetes are also at increased risk of experiencing stomach paralysis and pancreatitis overall, even without the treatments.
Persons:
semaglutide, –, Mohit Sodhi
Organizations:
Blockbuster, JAMA, Novo Nordisk, University of British Columbia, Nordisk
Locations:
U.S